Press releases
-
June
11
ADVITECH’S DERMYLEX ENTERS THE AUSTRIAN MARKET
TSX VENTURE EXCHANGE: AVI For immediate release
QUEBEC CITY, QUEBEC - June 11, 2009 - Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) today announces the execution of an exclusive agreement with Pelpharma Handels GmbH ("Pelpharma") for the distribution of Dermylex® in Austria.
-
May
29
ADVITECH REPORTS FIRST QUARTER 2009 FINANCIAL RESULTS AND HIGHLIGHTS
TSX VENTURE EXCHANGE: AVI For immediate release
QUEBEC CITY, QUEBEC - May 29, 2009 - Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) today announces the financial results for the first quarter ended March 31, 2009.
-
May
26
ADVITECH TO PRESENT RECENT DATA ON WOUND HEALING AT THE GORDON RESEARCH CONFERENCE
TSX VENTURE EXCHANGE: AVI FOR IMMEDIATE RELEASE
Quebec CITY, QuEbec - May 26, 2009 - Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) today announced that Dr Charles Doillon, M.D., Ph.D., Researcher at Centre de Recherche du Centre Hospitalier de l'Université Laval, who is leading Advitech's wound healing program, will be presenting a progress report on the Corporation's IM technological platform for wound management at Gordon Research Conference ("GRC") on Tissue Repair and Regeneration at Colby-Sawyer College, New London, NH, on Thursday June 18th, 2009.
-
May
07
ADVITECH ANNONCES POSITIVE RESULTS IN WOUND HEALING
TSX VENTURE EXCHANGE: AVI FOR IMMEDIATE RELEASE
Quebec CITY, QuEbec - May 7, 2009 - Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) announces today new in vivo data from its R&D wound healing program confirming once again the potential of the IM technology platform for wound healing applications.
-
April
17
ADVITECH OBTAINS SHAREHOLDERS APPROVAL OF THE PRIVATE PLACEMENT WITH AGECHEM AND PROCEEDS WITH THE CONVERSION OF DEBENTURES
TSX VENTURE EXCHANGE: AVI For immediate release
This news release is intended for distribution in Canada only and is not intended for distribution to United States newswire services or dissemination in the United States.
-
March
20
ADVITECH REPORTS THE FOURTH QUARTER AND YEAR-END RESULTS OF 2008
TSX VENTURE EXCHANGE: AVI For immediate release
QUEBEC CITY, QUEBEC - March 20, 2009 - Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) announces today its financial results for the fourth quarter of 2008 and for the year ended on December 31, 2008.
-
March
12
ADVITECH ANNOUNCES THE COMPLETION OF A CONDITIONAL PRIVATE PLACEMENT OF $1,000,000
TSX VENTURE EXCHANGE: AVI For immediate release
QUEBEC CITY - March 12, 2009 - Advitech Inc. (the "Corporation") (TSX-V : AVI), announced today that, further to the execution of the term sheet with AgeChem Venture Fund L.P. ("AgeChem") previously announced on February 10, 2009, it executed a binding conditional subscription agreement with AgeChem for the private placement (the "Private Placement") of 50,000,000 units at a price of $0.02 per unit.
-
February
10
ADVITECH EXECUTES A BINDING TERM SHEET FOR A $1M PRIVATE OFFERING
TSX VENTURE EXCHANGE: AVI For immediate release
QUEBEC CITY, QUEBEC - February 10, 2009 - Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) announces the execution of a binding term sheet for a $1 million private offering and changes to its management team.
-
November
28
ADVITECH REPORTS THIRD QUARTER 2008 FINANCIAL RESULTS
TSX VENTURE EXCHANGE: AVI FOR IMMEDIATE RELEASE
QUEBEC CITY, QUEBEC - November 28, 2008 - Advitech Inc. ("Advitech" or the "Company") (TSX Venture Exchange: AVI) today announced the financial results for the third quarter ended September 30 2008.
-
November
19
WOUND HEALING: ADVITECH ANNOUNCES AN AGREEMENT WITH URGO LABORATORIES
TSX VENTURE EXCHANGE: AVI FOR IMMEDIATE RELEASE
QUEBEC CITY, QUEBEC - November 19, 2008 - Advitech Inc. ("Advitech" or the "Company") (TSX Venture Exchange: AVI) announces today that it has signed an exclusive collaboration agreement with Laboratories Urgo, one of the European leaders in the wound healing market.
